Funding Details
- Awarder
- StartEngine
- Date Award
- March 21, 2023
- Vertical
- Healthcare
- Funding URL
- View Funding Page
Company Info
- Founding Year
- 2017
- Traction
- The liquid biopsy market is a nascent industry that is experiencing rapid growth in revenue. They are initially targeting the post-diagnosis oncology market with tests for metastatic lung, breast, and prostate cancer patients.
- Organizations Involved
- Stanford StartX Med, Formic Ventures, Exxclaim Capital
- Founders
- Adrianna Davies
- Company Description
- StrandSmart is developing a next-generation liquid biopsy (blood) test to enable precision medicine, or the ability to identify the biological driver of a tumor, allowing us to better match the right drug to the individual patient. They are pre-revenue and in development, working with academics and pharma to further validate their technology so that they can launch their blood tests to oncologists, giving them the tools to help improve and extend patients’ lives.
- Market
- Precision Medicine
- Location
-
San Diego,
CA,
US
- Coinvestors
- Stanford StartX Med, Formic Ventures, Exxclaim Capital
Links